지엘팜텍

204840KOSDAQ생활용품 도매업

48.8 / 100

Reference Date: 2026-07-24

Financial Score9.5 / 40

News Sentiment21.3 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE is above the industry average but the high debt ratio poses financial risk. Slightly down 3.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

GELPAMTEK primarily operates in pharmaceutical R&D services and has expanded into drug distribution and marketing. Its subsidiary, GELPHARMA, focuses on pharmaceutical manufacturing and sales, with key products including gastritis treatments, neuropathic pain medications, and specialty drugs. The company also generates revenue through technology fees and royalties from licensing its improved new drug technologies.

Number of Employees

32people

Average Salary

46.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

5054.36Industry Average 12.050.0Point

419.4x industry avg (risky)

PBR

3.17Industry Average 0.510.0Point

6.2x industry avg (risky)

ROE

0.06Industry Average 0.064.0Point

In line with industry avg

Debt Ratio

37.41Industry Average 11.050.0Point

3.4x industry avg (risky)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲17.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲80.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -13.7% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 5Neutral 0Negative 0Average Sentiment Score 85

Positive
지엘팜텍, 개량신약·퍼스트제네릭 성과 잇따라…"체질개선 본격화"
지엘팜텍이 개량신약과 퍼스트제네릭 사업에서 성과를 거두며 시장 경쟁력 강화를 보여주고 있다.
Positive
지엘팜텍, 로바엘젯·텔미엘탄정 등 잇단 품목허가
지엘팜텍이 고혈압 복합제 허가 획득으로 신약 경쟁력 강화.
Positive
지엘팜텍, 고혈압 치료제 텔미누보 퍼스트 제네릭 ‘텔미엘탄’ 품목.....
지엘팜텍의 고혈압 치료제 텔미엘탄의 품목허가 획득으로 순환기계 관련 포트폴리오 확장 및 시장 경쟁력 강화.

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 814Won52-week high 1,27452-week low 780

1-month return2.0Point

1m -3.78% (slight drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral주권매매거래정지 (주식의 병합, 분할 등 전자등록 변경, 말소)2026-07-14
Neutral임시주주총회결과2026-07-06
Neutral기타경영사항(자율공시) (소규모합병 승인 이사회 결의 결과 보고)2026-06-29